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Docetaxel and Exisulind in Previously Treated Non-small
Cell Lung Cancer (NSCLC) Patients: A Multicenter,
Phase II Clinical Trial
Glen J. Weiss, MD,* Everett E. Vokes, MD,† Paul A. Bunn, Jr, MD,‡ Lyn Magree, BS,‡
Jason Rusk, BA,§ Don Albert, MS,§ and Karen Kelly, MD
Purpose: This multicenter, phase II clinical trial was conducted to
evaluate the activity of the combination of docetaxel and exisulind
in advanced non-small cell lung cancer (NSCLC) patients who
failed a prior platinum-containing regimen.
Patients and Methods: Patients with measurable disease and ade-
quate organ function received exisulind (250 mg) given orally, twice
daily, and docetaxel (36 mg/m2) administered intravenously on days
1, 8, and 15 of a 4-week cycle for up to six cycles. In the absence
of disease progression or intolerable side effects, patients continued
taking 250 mg of exisulind orally, twice daily.
Results: Thirty-three patients (median age 60 years; range 34–77;
median performance status 1) were enrolled. There were no objec-
tive responses documented. Sixteen patients [48%, 95% confidence
interval (CI): 31%–66%] had stable disease after 8 weeks of treat-
ment. Median progression-free survival (PFS) was 2.1 months (95%
CI: 1.5–3.2 months); median overall survival time was 8.0 months
(range 0.2–25.9 months). Toxicity was moderate, with dose adjust-
ment for adverse event/toxicity required for docetaxel or exisulind in
13 (39.3%) patients. Grade 3/4 lymphopenia, neutropenia, and
anemia occurred in 48.5%, 12.1%, and 9.1% of patients, respec-
tively. Grade 3 or greater toxicity was seen in 12.1%, 6.1%, and 3%
of patients for nausea/vomiting, dyspnea, and abdominal pain, re-
spectively.
Conclusions: Treatment with exisulind and weekly docetaxel was
not active in NSCLC patients who failed a prior platinum-containing
regimen. Further study of this combination does not seem warranted.
Key Words: Non-small cell lung cancer, Exisulind, Docetaxel,
Chemotherapy.
(J Thorac Oncol. 2007;2: 933–938)
In 2006, an estimated 174,500 cases of lung cancer will bediagnosed, and an estimated 162,500 people will die from
this disease.1 Approximately 87% will have non-small cell
lung cancer (NSCLC) histology, and about two thirds of
those will present with advanced, unresectable disease.
Current American Society of Clinical Oncology guidelines
recommend the first-line use of doublet platinum-based che-
motherapy in advanced NSCLC and, alternatively, non–plat-
inum-containing chemotherapy may be used.2 Second-line
chemotherapy has prolonged survival in patients with ad-
vanced lung cancer. Two chemotherapy agents, docetaxel and
pemetrexed, are U.S. Food and Drug Administration ap-
proved in this setting. In addition, the epidermal growth
factor receptor inhibitor, erlotinib, showed a survival advan-
tage over placebo in previously treated patients, and it has
been approved for both second- and third-line treatment.
The induction of apoptosis in malignant cells is a
common mechanism of therapeutic agents to destroy tumor
cells. Nevertheless, most agents achieve apoptosis by indirect
approaches. Thus, agents that could directly target the apo-
ptotic pathway would be of additional value. Exisulind, a
sulfone metabolite of the nonsteroidal anti-inflammatory drug
(NSAID) sulindac, possesses proapoptotic properties. It in-
hibits cyclic GMP (cGMP) phosphodiesterases 2 and 5,
which are often overexpressed in a variety of cancers (Figure
1). This inhibition leads to programmed cell death, as it
causes sustained elevation of cGMP, leading to the activation
of cGMP-dependent protein kinase G (PKG).3,4 The pathway
to apoptosis continues with PKG activation promoting pro-
teasomal degradation of -catenin and activation of c-Jun
NH2-terminal kinase (JNK).2 Exisulind demonstrated in vitro
tumor growth inhibition in breast5 and colon cancer6 cell lines
and in vivo tumor growth inhibition of colon, bladder, breast,
prostate, and lung cancers in rodent models.7–9 We previously
have shown that exisulind produced synergistic growth inhi-
bition when combined with docetaxel in vitro 10 and in vivo
when the combination significantly improved survival in an
orthotopic lung cancer model.10,11
Initial clinical investigations involved the use of exisu-
lind as a chemopreventative agent in familial adenomatous
polyposis (FAP).12 Exisulind (250 mg, given orally, twice
daily) was also studied in a randomized, double-blind, pla-
cebo-controlled trial of 96 high-risk men with increasing PSA
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after radical prostatectomy.13 Exisulind inhibited the increase
in PSA overall and prolonged PSA-doubling time in high-risk
patients compared with placebo, and it was well tolerated.
The most frequent toxicities observed with exisulind were
asthenia, dyspepsia, increased alanine aminotransferase, nau-
sea, abdominal and back pain, and viral infection. Exisulind
has been studied alone as an anticancer agent. In a phase I
study, exisulind was administered to 15 heavily pretreated
patients with NSCLC.14 Dose-limiting toxicities were gastro-
intestinal discomfort and elevated liver-function tests, with a
maximum tolerated dose of 250 mg twice daily for exisulind.
Although no objective responses were seen, two patients had
stable disease for 14 and 15 weeks.
Because of its novel mechanism of action and disease
stabilization, interest focused on combining exisulind with
cytotoxic agents that have complementary effects on tumor
cells.15 A phase I dose-escalation and pharmacokinetic study
of exisulind (150 –250 mg, twice daily) and docetaxel
(30 –36 mg/m2, administered intravenously) on days 1, 8,
and 15, every 28 days, was carried out at the University of
Colorado.4 No dose-limiting toxicities were seen during
the first cycle. The maximum dose of docetaxel was 36
mg/m2 in combination with 250 mg of exisulind twice
daily. No objective responses were observed in the 20
patients receiving the combination of exisulind and do-
cetaxel, although a third of patients maintained at stable
disease levels for 3 to 12 cycles, and two patients (one with
prostate cancer and one with carcinoid) remained on the
study for 10 and 12 cycles.
At the time of the study, weekly docetaxel was thought
to have equivalent efficacy with lower toxicity compared with
every-3-week dosing.16 On the basis of preclinical and clin-
ical data, this phase II study combining docetaxel and exisu-
lind was initiated in patients with NSCLC failing a prior
platinum-containing regimen. Here, we report the final results
of that phase II trial.
PATIENTS AND METHODS
Patient Selection
Patients with confirmed advanced NSCLC that pro-
gressed or those who had received a platinum-based chemo-
therapy regimen in the past 6 months were eligible for this
study. Other eligibility criteria included the following: (a)
measurable disease; (b) age 18 years; (c) life expectancy
3 months; (d) Southwest Oncology Group performance
status 2;17 (e) no prescription or over-the-counter NSAIDs
for 2 weeks before enrollment (patients taking a cumulative
monthly dose of aspirin of 3250 mg for cardiovascular
prevention were not excluded from the study); (f) no chemo-
therapy or radiotherapy within 2 weeks or investigational
agent within 4 weeks of study entry with full recovery from
the acute effects of prior therapy; and (g) adequate hemato-
poietic, hepatic, and renal function.
Patients with uncontrolled or symptomatic brain metas-
tases, significant medical conditions, peripheral neuropathy
greater than grade 1, or known hypersensitivity to sulindac,
taxanes, or other drugs formulated with polysorbate 80, were
excluded. Women of child-bearing age were required to have
a negative pregnancy test before study entry and were re-
quired to be on adequate birth control while on the study.
Informed consent was obtained in accordance with to federal
and institutional guidelines.
Study Design
This was a two-center phase II trial of the combination
of exisulind and docetaxel for advanced NSCLC patients who
had failed a prior platinum-based chemotherapy regimen.
Patients were enrolled prospectively at the University of
Colorado and the University of Chicago. The primary end-
point of the study was objective response rate. Secondary
endpoints included progression-free survival (PFS), median
overall survival (OS), and toxicity.
Treatment
Docetaxel (36 mg/m2) was administered intravenously
for 30 minutes on days 1, 8, and 15 for an every-28-days
cycle for a maximum of six cycles. All patients received
dexamethasone (8 mg, administered intravenously) before
docetaxel infusion. The use of diphenhydramine was op-
tional. Exisulind (250 mg, administered orally, twice daily)
was started on day 1 through day 28 of each cycle and, after
six cycles, was continued as a single agent until disease
progression or intolerable toxicity.
Salicylates (except 3250 mg of aspirin for cardio-
vascular prevention) and NSAIDs (except ibuprofen or
naproxen) were not allowed 2 weeks before enrollment and
for the duration of the study.
Dose Modifications
Toxicities were graded according to the National Can-
cer Institute CTC, version 2.0.18 First- and second-reduction
doses were as follows: exisulind (200 mg, administered
orally, twice daily; and 150 mg, administered orally, twice
daily), and docetaxel (30 and 25 mg/m2, respectively, both
administered intravenously). If an elevated bilirubin (grade 3
FIGURE 1. Exisulind mechanism of action. Exisulind inhibits
cyclic GMP (cGMP)-phosphodiesterases 2 and 5. This inhibi-
tion leads to programmed cell death, as it causes sustained
elevation of cGMP, leading to the activation of cGMP-de-
pendent protein kinase G (PKG). The pathway to apoptosis
continues with PKG activation promoting proteasomal deg-
radation of -catenin and activation of c-Jun NH2-terminal
kinase (JNK).
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or any elevation) or any grade 3 hepatotoxicity occurred,
exisulind and docetaxel dosing was interrupted. When the
patient had recovered to grade 1 toxicity, both drugs were
restarted at their respective dose-reduction levels. Docetaxel
was also reduced for an elevated alanine transferase (ALT) to
1.6 times the upper limit of normal (ULN), and by one dose
level for any hematologic toxicity of grade or higher. Any
patient requiring a dose-level reduction continued to receive
the reduced dose for the remainder of the study. If there was
a recurrence of grade 3 toxicity after two dose reductions,
the patient could no longer receive that drug. If one drug was
stopped for toxicity, the patient could continue the other drug
at the discretion of the principal investigator.
Patients could not receive docetaxel unless their abso-
lute neutrophil count (ANC) was 1500/ul and their platelet
count was 100,000/ul. The use of colony stimulating sup-
port agents were to be used according to American Society of
Clinical Oncology 2000 guidelines.19 Patients were removed
from the study if they had intolerable toxicity or disease
progression, or if they withdrew consent.
Exisulind was supplied by OSI Pharmaceuticals Inc.,
successor-in-interest to Cell Pathways, Inc. (Melville, NY), in
100- or 150-mg gelatin capsules. Docetaxel was commer-
cially available from Sanofi-Aventis Pharmaceuticals, Inc.
Patient Assessment
Baseline assessment included a complete medical his-
tory, physical examination, assessment of performance status,
complete blood count with a differential, comprehensive
metabolic panel, plus phosphate, uric acid, and lactate dehy-
drogenase. A urinalysis and a serum pregnancy test (as
appropriate) were performed before treatment. Pretreatment
studies also included an electrocardiogram, and relevant ra-
diographic studies to evaluate all measurable and assessable
sites of disease. Patient adherence was monitored by pill
counts and dosing diaries. Weekly blood counts were per-
formed before docetaxel administration. Physical examina-
tion, toxicity evaluation, documentation of concurrent medi-
cations, complete laboratory analysis, and assessment of
performance status were performed at each cycle.
Radiographic evaluations for disease status assessment
were repeated after every other course, using the WHO
criteria.20 A complete response was defined as the disappear-
ance of all measurable and assessable disease for at least two
measurements performed at least 4 weeks apart without
worsening of disease-related symptoms or declining perfor-
mance status. A partial response required at least a 50%
reduction in the sum of the product of the bidimensional
measurements of all lesions documented by at least two
measurements separated by a minimum of 4 weeks. Any
increase in the size of a lesion by 25% or the appearance of
a new lesion was considered disease progression. Patients
continued on treatment in the absence of disease progression
or intolerable toxicity.
Statistical Analysis
Treatment success for an individual patient was defined
as the occurrence of a complete or partial response. The
smallest success proportion that would justify further study of
the proposed regimen was 15%. A two-stage Fleming design
was applied.21 This design uses 26 or 52 patients to test the
null hypothesis that the true success proportion in a given
patient population is, at most, 5%.
Stage 1: Enter 26 patients. If no successes are observed,
accrual will be terminated and the regimen declared inef-
fective. If five or more successes are observed, accrual may
be terminated and the trial declared a success. Otherwise,
proceed to stage 2.
Stage 2: Enter an additional 26 patients. If five or fewer total
successes are observed, the regimen will be declared inef-
fective. If six or more successes are observed, the trial will
be declared a success.
This scheme provided an 81% power to conclude a
success given a true response rate of 15%, and 4.6% proba-
bility of falsely concluding success given a true response rate
of less than 5%.
Actuarial survival curves were generated using the
Kaplan–Meier method.22
RESULTS
Patient Characteristics
Between November 7, 2001 and January 14, 2004, 33
eligible patients were entered onto the study; their character-
istics are listed in Table 1. There were 17 men and 16 women.
The median age was 60 years (range 34–77), 84% had a
performance status1, and 70% were Caucasian. No patients
had brain metastases. There were 26 patients evaluable for
response, and all 33 patients were evaluable for toxicity.
Thirty-three patients were enrolled in the trial to fulfill the
TABLE 1. Patient Characteristics
No. of Patients
(n  33) %
Gender
Male 17 52
Female 16 48
Median age (range) 60 years (34–77)
Southwest Oncology Group performance status
0 3 9
1 25 76
2 5 15
Race
Caucasian 23 70
Black 8 24
Asian 2 6
Extralymphatic metastatic sites
Liver 6 18
Bone 3 9
Adrenal 2 6
Time elapsed since prior chemotherapy
3 months 24 73
3–6 months 8 24
6 months 1 3
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Fleming Stage 1 design; seven patients were removed from
study before they were evaluable for response. These seven
patients had progressive disease before radiologic assess-
ment for efficacy could be determined according to proto-
col guidelines.
Efficacy
No objective responses were observed. Sixteen patients
(48%, 95% confidence interval (CI): 31%–66%) had stable
disease after treatment. Median PFS was 2.1 months (95%
CI: 1.5–3.2 months). Median follow-up time was 8.0 months
(range 0.2–25.9 months). Figure 2A shows the actuarial PFS
curve for all patients. The median survival curve for the entire
population is shown in Figure 2B. Median survival was 8.0
months, and the 1-year survival estimate was 38.1% (95% CI:
20.0%–56.4%). Twenty-one patients received additional ther-
apy after removal from the study. Systemic therapy was
received by 17 patients (range of one to four regimens), with
gefitinib being most frequent (n  10). Seven patients re-
ceived radiation therapy after removal from the study.
Study Drug Administration and Toxicity
Patients received a median of two cycles of docetaxel
and two cycles of exisulind. Three patients completed six
cycles of docetaxel, and two patients completed eight cycles
of docetaxel at the discretion of the principal investigator.
Overall, 90 cycles of therapy (combined or single agent) were
delivered.
Dose reductions were common. Dose adjustments for
docetaxel included five (15%) attributable to adverse events/
toxicity (hyperlacerimation [1], rash [1], nausea and/or vom-
iting [2], and diarrhea [1]) and four (12%) attributable to
laboratory abnormalities (neutropenia [2], elevated transami-
nases [1], and elevated bilirubin [1]). Dose reductions for
exisulind included five (15%) attributable to toxicities, which
included diarrhea (1), digital erythema (1), rash (1), elevated
bilirubin (1), and elevated AST (1). Nine (27%) patients
discontinued study therapy (exisulind and/or docetaxel) be-
cause of adverse events/toxicities, including severe nausea
and vomiting (1); mental status changes (1); arthralgia, as-
thenia, ataxia, chest pain, dizziness, elevated liver-function
tests, and lower-extremity pain (1); cholecystitis (1); onych-
omycosis (1); radiation pneumonitis (1); fatigue (1); abdom-
inal pain, fatigue, and elevated liver-function tests (1); and
neuropathy (1). Only two patients continued on docetaxel
when exisulind was discontinued.
Laboratory hematologic and nonhematologic toxicity
was moderate (Table 2). Grade 3/4 lymphopenia, neutrope-
nia, anemia, and thrombocytopenia occurred in 48.5%, 12.1%,
9.1%, and 3.0% of patients, respectively. No cases of febrile
neutropenia occurred. Grade 3/4 abnormalities in serum chem-
istry were seen in ALT (9.1%), total bilirubin (6.1%), and
creatinine (6.1%). Severe toxicity was seen in 12.1%, 6.1%,
3%, and 3% of patients for nausea/vomiting, dyspnea, ab-
dominal pain, and increased lacrimation, respectively (Table
3). Nail disorders or increased lacrimation were reported in
six patients each (Table 3). There were no toxic deaths.
DISCUSSION
This phase II trial of weekly docetaxel plus exisulind as
second-line therapy was tolerable, but it failed to produce
objective responses. One possible explanation for the lack of
response is the use of the weekly docetaxel schedule. Two
randomized trials comparing weekly versus docetaxel every 3
weeks in advanced NSCLC did not show a significant differ-
ences in survival or response rates.23,24 Camps et al.23 studied
259 advanced NSCLC patients previously treated with plat-
inum-based chemotherapy comparing docetaxel (75 mg/m2)
every 3 weeks versus docetaxel (36 mg/m2) weekly for six
consecutive weeks every 8 weeks. The response rates were
9.3% and 4.8%, and median overall survival was 6.6 and 5.4
months (p 0.076), in the every-3-weeks versus weekly arm,
respectively. The second study24 involved 220 advanced
NSCLC patients in two dosing schemes in the second-line
setting (docetaxel [75 mg/m2] every 3 weeks for six cycles
versus docetaxel [33.3 mg/m2] weekly for six consecutive
weeks every 8 weeks for two cycles). The response rates were
FIGURE 2. (A) Median progression-free survival (PFS) was 2.1 months. (B) Median survival and 1-year survival rates were 8.0
months and 38.1%, respectively.
Weiss et al. Journal of Thoracic Oncology • Volume 2, Number 10, October 2007
Copyright © 2007 by the International Association for the Study of Lung Cancer936
2.7% and 5.5%, and median overall survival was 7.3 versus
6.3 months (p  not significant) in the every-3-weeks versus
weekly arm, respectively.
Another possible reason for the lack of response was
that the study only included patients who had failed a
platinum-based regimen in the past 6 months. In fact, the
majority of patients enrolled (73%) failed systemic therapy
in the first 3 months—this most likely suggests a drug-
refractory population.
Most likely is the lack of antitumor activity of exisulind
when combined with chemotherapy. The Eastern Cooperative
Group conducted a phase II trial of carboplatin and gemcit-
abine with exisulind in untreated, advanced NSCLC patients
in 58 patients using gemcitabine (1000 mg/m2) on days 1 and
8 and carboplatin (AUC  5) on day 1, every 21 days, along
with exisulind (250 mg, orally) twice daily.25 Grade 3 and 4
hematologic toxicities were neutropenia (35% and 21%) and
thrombocytopenia (23% and 7%). Grade 3/4 nonhematologic
toxicity was nausea and fatigue, seen in 14% and 18% of
patients, respectively. The overall response rate was 17%,
and median survival was 7.1 months. The authors conclude
that the addition of exisulind did not have benefit over
standard chemotherapy. CPI-028, a randomized phase III trial
of docetaxel with or without exisulind, completed accrual,
with results expected in the near future.
The CALGB has reported on a phase II study of
carboplatin, etoposide, and exisulind in 43 patients with
extensive-stage small-cell lung cancer.26 Toxicity was evalu-
able in all 43 patients, with grade 4 toxicities of neutropenia
(43%), anemia (2%), and hypokalemia (2%), and grade 3
toxicities of thrombocytopenia (38%), neutropenia (24%),
febrile neutropenia (17%), anemia (14%), hyperglycemia
(12%), and fatigue (10%). There was one treatment-related
death (stroke). Thirty-eight patients were assessable for re-
sponse, with 15% complete and 66% partial. The median
overall survival was 10.5 months, and the study did not meet
its primary endpoint.
Numerous targeted agents have failed after first-line
therapy, including studies of epidermal growth factor recep-
tor tyrosine kinase inhibitors in combination with standard
chemotherapy (concurrent administration),27–30 a metallopro-
teinase inhibitor,31 a retinoid X-receptor–specific ligand,32
and an antisense protein kinase C-alpha inhibitor.33 Never-
theless, there are also examples where single agents that
produce stable disease in the advanced setting show enhanced
activity with chemotherapy, such as bevacizumab in combi-
nation with carboplatin and paclitaxel.34
Overall, the exisulind and docetaxel combination had
moderate toxicity, mainly with an increase in hepatotoxicity,
nausea, and vomiting. The high incidence of lymphopenia
observed is typical for docetaxel. The lack of a response in
the 26 evaluable patients fulfilled stage 1 of the Fleming
design to halt the study. According to these results, this
combination of docetaxel and exisulind given in these doses
and schedule should not be pursued in advanced NSCLC
patients who have failed a prior platinum-based therapy.
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